近年来，双特异性抗体（双抗）通过提高免疫细胞靶向杀伤能力、阻断多信号通路产生协同作用等方式，在肿瘤免疫治疗领域呈现独特的治疗潜力。全球范围内，目前有＞200种用于抗肿瘤的双抗药物处于临床研究阶段，15种双抗获批用于治疗恶性血液肿瘤或实体瘤。双抗虽在恶性血液肿瘤中的治疗效果较好，但在实体瘤治疗中，如靶点选择、药物递送、安全性以及耐药性等方面仍面临诸多挑战。此文总结了已上市双抗在肿瘤治疗中的临床应用及研究进展，以为双抗药物的研发及临床应用提供参考。

In recent years， bispecific antibodies （BsAbs） have presented unique therapeutic potential in tumor immunotherapy by improving the targeted killing capacity of immune cells and blocking multiple signaling pathways to produce synergistic effects. Over 200 BsAbs for antitumor therapy are currently in clinical development worldwide， with 15 approved for use in hematologic malignancies or solid tumors. BsAbs are effective in treating malignant hematologic tumors. However， many challenges remain in solid tumor therapy， including target selection， drug delivery， safety and drug resistance. This article summarizes the clinical applications and research progress of licensed BsAbs in cancer treatment， providing a reference for BsAbs development and clinical utilization.